Статья

Practical experience of using riamilovir in treatment of patients with moderate COVID-19

A. Sabitov, V. Belousov, A. Edin, E. Oleinichenko, E. Gladunova, E. Tikhonova, T. Kuzmina, Y. Kalinina, P. Sorokin,
2020

The article evaluates the results of Riamilovir use in treatment of patients with a moderate form of the disease caused by a new strain of the SARS-CoV-2 virus. It was found that the average time required to complete resolution of symptoms during treatment with the drug was 6-7 days. The first negative result of PCR analysis for the SARS-CoV-2 virus was registered on the 10-11 day of therapy; two consecutive negative PCR results for the SARS-CoV-2 virus were registered in the majority of patients by day 14-19 of treatment in 63±4.28%. The body temperature of the majority of patients (75%) returned to normal by the 4 day of treatment. CT scan showed improvement in the lungs of patients: a repeated CT scan performed on average on day 19 from the start of therapy showed no lung damage or no progression in 10±3.0% of patients following therapy. The CT scan of the lungs performed in 1-2 months after the treatment showed that the number of patients with no lung damage increased to 27±4.44%. As a result of treatment, a decrease in the C-reactive protein index was observed in patients. The tolerability level of the drug was assessed as good: no adverse events or significant deviations in laboratory parameters were detected. th th

Цитирование

Похожие публикации

Документы

Источник

Версии

  • 1. Version of Record от 2020-01-01

Метаданные

Об авторах
  • A. Sabitov
    Ural State Medical University
  • V. Belousov
    Ural State Medical University
  • A. Edin
    A.I. Burnasyan Federal Medical Biophysical Center FMBA
  • E. Oleinichenko
    Polyclinic No. 3 of the Administrative Department of the President of the Russian Federation
  • E. Gladunova
    Samara State Medical University
  • E. Tikhonova
    Voino-Yasenetsky Krasnoyarsk State Medical University
  • T. Kuzmina
    Voino-Yasenetsky Krasnoyarsk State Medical University
  • Y. Kalinina
    Voino-Yasenetsky Krasnoyarsk State Medical University
  • P. Sorokin
    LLC Azol Pharma
Название журнала
  • Antibiotiki i Khimioterapiya
Том
  • 65
Выпуск
  • 7-8
Страницы
  • 27-30
Номер гранта
  • undefined
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC BY
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus